Close Menu
bkngpnarnaul
  • Home
  • Education
    • Biology
    • Chemistry
    • Math
    • Physics
    • Science
    • Teacher
  • E-Learning
    • Educational Technology
  • Health Education
    • Special Education
  • Higher Education
  • IELTS
  • Language Learning
  • Study Abroad

Subscribe to Updates

Please enable JavaScript in your browser to complete this form.
Loading
What's Hot

Your Essential Back-to-School Checklist for Teachers

August 31, 2025

Beet juice secretly helps older adults lower blood pressure in just two weeks

August 31, 2025

Mathletics Works: New Study Proves Clear Link to NAPLAN Success

August 31, 2025
Facebook X (Twitter) Instagram
Monday, September 1
Facebook X (Twitter) Instagram Pinterest Vimeo
bkngpnarnaul
  • Home
  • Education
    • Biology
    • Chemistry
    • Math
    • Physics
    • Science
    • Teacher
  • E-Learning
    • Educational Technology
  • Health Education
    • Special Education
  • Higher Education
  • IELTS
  • Language Learning
  • Study Abroad
bkngpnarnaul
Home»Chemistry»Macrocyclic peptide start-up scores $1.5 billion deal with Argenx
Chemistry

Macrocyclic peptide start-up scores $1.5 billion deal with Argenx

adminBy adminJuly 1, 20251 Comment3 Mins Read0 Views
Share Facebook Twitter Pinterest LinkedIn Tumblr Email WhatsApp Copy Link
Follow Us
Google News Flipboard Threads
Macrocyclic peptide start-up scores .5 billion deal with Argenx
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link


Macrocyclic peptide start-up scores .5 billion deal with Argenx

Credit: Unnatural Products

Cameron Pye is the cofounder and CEO of Unnatural Products.

The biopharma company Argenx has tapped the start-up Unnatural Products to develop macrocyclic peptides with the goal of bolstering its inflammatory and immunological drug roster with once-daily pills.

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the double-digit millions, milestone payments, and research and development funding. Argenx will also make an equity investment in Unnatural Products as part of the deal.

The timing couldn’t be better for Unnatural Products, CEO Cameron Pye says. It has collaborations underway with BridgeBio Pharma and Merck & Co. for rare diseases and cancer. Finding new equity investment has been difficult amid the downturn in the biotechnology market, making partnerships an attractive business strategy. Pye says he and his team had been planning to reach out to Argenx about a potential deal when, about 6-9 months ago, Argenx’s business development group approached the start-up first.

“We’ve always found [collaborations] to be great opportunities, not just to bring dollars in the door when the equity markets can be a little bit challenging—as they have been for, say, the last half-decade—but also to bring some additional learnings and strategy to the table,” Pye says.

Backing from Argenx also helps Unnatural Products “claw our way up the validation ladder as a small company,” Pye says. Argenx focuses on immunology and sells antibody drugs for myasthenia gravis, primary immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. Fueled by new US Food and Drug Administration approvals of its lead product, Vyvgart, Argenx turned a profit last year for the first time.

Like other antibodies, Vyvgart—generically called efgartigimod—must be delivered by infusion or injection. So does the second investigational drug in Argenx’s pipeline, empasiprubart. In contrast, Unnatural Products intends to develop oral macrocyclic peptides that can be given as simple pills.

Macrocyclic peptides are small chains of amino acids that form loops. The shape is important: it provides more surface area for the peptides to disrupt protein-protein interactions, and it helps the drug stay intact inside the body—unlike traditional antibodies, which are vulnerable to breakdown by proteases. That stability also means macrocyclic peptides should remain stable on pharmacy shelves without the cold storage that traditional antibodies require.

With antibodies, “patients now suddenly have options that they never had before,” Pye says. “They can treat and manage their diseases in a way that was really unmanageable even 5 or 10 years ago, but they come with a lot of asterisks,” he adds. “What we’re looking to do is remove those asterisks and provide a shelf-stable, once-daily, oral pill solution for these things.”

Pye declines to name the exact targets or diseases involved in the Argenx partnership or to specify any clinical development timelines other than “as fast as possible.” The deal encompasses multiple targets of interest that Argenx has identified, which are involved in multiple indications, according to a press release.

Meanwhile, the 40-person team at Unnatural Products continues to advance its internal pipeline alongside the partnered assets. Pye says it is also in the process of raising a series B financing round.

Chemical & Engineering News

ISSN 0009-2347

Copyright © 2025 American Chemical Society



Source link

Argenx billion deal Macrocyclic peptide Scores startup
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email WhatsApp Copy Link
yhhifa9
admin
  • Website

Related Posts

Chemistry

A tiny chip may have solved one of clean energy’s biggest problems

August 30, 2025
Chemistry

Enhanced efficiency of zinc oxide hydroxyapatite nanocomposite in photodegradation of methylene blue, ciprofloxacin, and in wastewater treatment

August 29, 2025
Chemistry

Enzyme-driven process explains how NeuO selectively stains living neurons, solving a decade-old mystery

August 28, 2025
Chemistry

What is Gas Chromatography? | ChemTalk

August 27, 2025
Chemistry

Fields of Data: Mapping Vulnerability in Bengal’s Rice Belt

August 26, 2025
Chemistry

The spin-offs from adding citations to blog posts.

August 25, 2025
View 1 Comment

1 Comment

  1. 🔐 Message- + 1.660534 BTC. Continue >>> https://graph.org/Payout-from-Blockchaincom-06-26?hs=9fcab2bdcd56cd96aed74b81088d87cc& 🔐
    🔐 Message- + 1.660534 BTC. Continue >>> https://graph.org/Payout-from-Blockchaincom-06-26?hs=9fcab2bdcd56cd96aed74b81088d87cc& 🔐 on July 1, 2025 3:43 pm

    rcj2lj

    Reply
Leave A Reply Cancel Reply

Top Posts

2024 in math puzzles. – Math with Bad Drawings

July 22, 202520 Views

Testing Quantum Theory in Curved Spacetime

July 22, 20259 Views

How AI Is Helping Customer Support Teams Avoid Burnout

May 28, 20257 Views

Chemistry in the sunshine – in C&EN

August 9, 20256 Views
Don't Miss

Irina’s Spring Semester in Valencia, Spain 

By adminAugust 31, 20252

36 Eager to follow in the footsteps of a college student who studied abroad in…

Living Costs in Limerick | Study in Ireland

August 30, 2025

These 3 College Students Studied Abroad in Greece

August 27, 2025

Taylor’s Spring Semester in Athens

August 23, 2025
Stay In Touch
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
  • YouTube
  • Vimeo

Subscribe to Updates

Please enable JavaScript in your browser to complete this form.
Loading
About Us
About Us

Welcome to Bkngpnarnaul. At Bkngpnarnaul, we are committed to shaping the future of technical education in Haryana. As a premier government institution, our mission is to empower students with the knowledge, skills, and practical experience needed to thrive in today’s competitive and ever-evolving technological landscape.

Our Picks

Your Essential Back-to-School Checklist for Teachers

August 31, 2025

Beet juice secretly helps older adults lower blood pressure in just two weeks

August 31, 2025

Subscribe to Updates

Please enable JavaScript in your browser to complete this form.
Loading
Copyright© 2025 Bkngpnarnaul All Rights Reserved.
  • About Us
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions

Type above and press Enter to search. Press Esc to cancel.